## ICMJE DISCLOSURE FORM

Date:	Oct. 20	<sup>oth</sup> , 2021
Your Name	: <u>Phili</u>	<u>ippe Merle</u>
Manuscript	:Title:	Simultaneous blockage of the PD-1/PD-L1 axis and VEGF pathway are clinically relevant
in hepatoc	ellular o	carcinoma therapy
Manuscript	number	(if known):DMR-21-76
In the inter	est of tra	ansparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	xNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastxIPSEN	36 months
3	Royalties or licenses	x None	
4	Consulting fees	x None	

5	Payment or honoraria for	x None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or	x None	
	pending		
9	Participation on a Data	Advisory Board	Roche, AstraZeneca, MSD, Eisai, Ipsen, Bayer
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	y None	
11	•	x None	
11	group, paid or unpaid	x None	
11 12	group, paid or unpaid	x None	
	group, paid or unpaid Stock or stock options		
	group, paid or unpaid Stock or stock options  Receipt of equipment,		
	group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
	group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-		
12	group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services	x None	
12	group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	x None	
12	group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	x None	
12	group, paid or unpaid Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	x None	

Irrespective of the present manuscript:  1) Grants: Ipsen					
2)	AdBoard: Roche, AstraZeneca, MSD, Eisai, Ipsen, Bayer				

Please place an "X" next to the following statement to indicate your agreement:

\_x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.